Jane Wolstenholme BA MSc PhD
- Cancer Screening
- Contingent Valuation
- Priority Setting
- Pluddemann Annette, Price Christopher P, Thompson Matthew, Wolstenholme Jane, and Heneghan Carl (2011) Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin. Br J Gen Pract, 61(583):139-40.
- Rivero-Arias Oliver, Gray Alastair, and Wolstenholme Jane (2010) Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom. Cost Eff Resour Alloc, 8:6.
- Rivero-Arias Oliver, Ouellet Melissa, Gray Alastair, Wolstenholme Jane, Rothwell Peter M, and Luengo-Fernandez Ramon (2010) Mapping the modified Rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Med Decis Making, 30(3):341-54.
- Legood Rosa, Wolstenholme Jane, and Gray Alastair (2009) From cost-effectiveness information to decision-making on liquid-based cytology: Mind the gap. Health Policy, 89(2):193-200.
- Rivero-Arias Oliver, Wolstenholme Jane, Gray Alastair, Molyneux Andrew J, Kerr Richard SC, Yarnold Julia A, and Sneade Mary (2009) The costs and prognostic characteristics of ischaemic neurological deficit due to subarachnoid haemorrhage in the United Kingdom. Evidence from the MRC International Subarachnoid Aneurysm Trial. J Neurol, 256(3):364-73.
|Tel||+44 (0)1865 289 269|
|Fax||+44 (0)1865 289 271|
Jane Wolstenholme is a senior researcher at the University of Oxford Health Economics Research Centre (HERC). She has been a health economist since 1994 with research positions at Nottingham and Oxford Universities. Her main research interests lie in the areas of economic evaluation from applied and methodological perspectives. She is currently undertaking a number of projects across various disease areas and interventions; modelling studies include the cost-effectiveness of prostate cancer screening in the UK (HTA and CRUK funded) and in Ireland (Irish Health Research Board funded), cost-effectiveness of home-monitoring for neutropenia in breast and colorectal cancer patients (TSB funded), cost-effectiveness of diagnostic technologies in primary care settings (NIHR programme grant), economic evaluations alongside trials include the cost-effectiveness of dietary and physical activity interventions in breast cancer patients (RfPB funded), cost-effectiveness of early use of antibiotics for at risk children with influenza in primary care (NIHR programme grant), cost-effectiveness of oral corticosteroids for sore throat (NSPC funded).